FDA Approves Oral Drug Mayzent To Treat Multiple Sclerosis, Novartis Expected To Get $1.7 Billion In Revenue By 2026
The U.S. Food and Drug Administration today approved Mayzent (siponimod) tablets by Novartis to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome,…
